We are doing this study to find out if the drugs talquetamab and teclistamab are a safe and effective option for people with multiple myeloma that has come back after treatment (relapsed) or is not improving with treatment (refractory).

Relapsed or Refractory Multiple Myeloma

Adults ages 18+ who are diagnosed with relapsed or refractory multiple myeloma.

For more information about who can join this study, please contact the study team at quinna.marshburn@duke.edu.

The study is divided into three periods: screening period, study dosing period, and a safety follow-up period.

If you choose to join this study, during the screening period you will:

• Have a tumor biopsy
• Have imaging scans (CT, MRI, and echocardiogram)
• Have physical exams and blood draws

If we find that you are eligible during the screening period, you will proceed to the dosing period. During this period, you will get a random assignment (fair, equal chance) to 1 of 3 study arms:

• Arm A: If you are in this arm, you will get a regimen of both talquetamab and pomalidomide (Tal-P).
• Arm B: If you are in this arm, you will get a regimen of both talquetamab and teclistamab (Tal-Tec).
• Arm C: If you are in this arm, you will get a regimen of elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).

After you finish your assigned study regimen, we will schedule you to return to our clinic for follow-up visits to keep track of your health and how you are feeling.